Argenx (ENXTBR:ARGX) Stock Faces Margin Compression As 32.3% Profitability Tests Bullish Narrative

argenx (ENXTBR:ARGX) has put up another busy quarter, with Q2 2026 revenue at roughly US$1.5 billion and basic EPS of US$7.57, while trailing twelve month revenue sits at about US$5.3 billion and EPS at US$27.72, supported by net income of US$1.7 billion over that period. Over recent quarters the company has seen revenue move from US$967.63 million in Q2 2025 to US$1.54 billion in Q2 2026, alongside basic EPS stepping from US$4.02 to US$7.57. This sets the stage for investors to focus on how these headline gains translate into the sustainability of argenx's margins.

See our full analysis for argenx.

With the latest figures set, the next step is to see how argenx's reported growth and profitability stack up against the market narratives that have built around the stock and where those stories might now need refining.

See what the community is saying about argenx

argenx margins sit at 32.3% on trailing basis

• Trailing twelve month net income of about US$1.7 billion on US$5.3 billion of revenue works out to a 32.3% net margin, compared with 41.0% in the prior year period cited in the analysis.
• Consensus narrative points to Vyvgart expansion and new formulations as long term margin drivers. However, the combination of US$1.7 billion of trailing net income and a lower 32.3% margin shows that high current spending, including Q2 2026 R&D of US$328 million and SG&A of US$325 million, is still weighing on how much of that revenue turns into profit.
  • This margin profile sits alongside forecast earnings growth of about 22.1% per year, so readers need to weigh the current 32.3% level against expectations that margins move higher over time.
  • The drop from 41.0% to 32.3% also interacts with analyst expectations that margins reach 35.0% in a few years, which assumes some reversal of the recent compression seen in the trailing figures.

Q2 2026 EPS of US$7.57 fuels the bullish growth story

• argenx reported basic EPS of US$7.57 on US$1.5 billion of Q2 2026 revenue and US$27.72 over the last twelve months, compared with quarterly EPS figures ranging from US$2.78 in Q1 2025 to US$8.63 in Q4 2025 in the data provided.
• Bulls highlight rapid Vyvgart adoption and a pipeline they expect to lift earnings to US$4.0 billion, with EPS of US$55.85 by around 2029. The current trailing EPS of US$27.72 and forecast earnings growth of about 22.1% per year heavily support the idea that argenx is already operating at a scale that lines up with that growth narrative.
  • The step from US$245.5 million of net income in Q2 2025 to US$472 million in Q2 2026 underpins the bullish view that new indications and geographies are already feeding through to the bottom line rather than being purely theoretical.
  • At the same time, the 32.3% trailing margin compared with 31.4% used in some bullish assumptions keeps attention on whether future margin expansion to 38.1% is realistic given recent spending levels.

On these numbers, many bulls see argenx as already partway along the path they expect over the next few years, which is why they focus so much on how sustainable this pace of earnings growth looks from here. 🐂 argenx Bull Case

Rich 33.4x P/E keeps bearish valuation worries alive

• At a share price of €804.40 and trailing EPS of US$27.72, argenx is referenced with a P/E of 33.4x, above the European biotech average of 16.6x and the peer average of 28.1x, while also being compared with a DCF fair value of €2,466.70 and an analyst price target of €889.59 in the analysis dataset.
• Skeptics point out that this richer 33.4x P/E alongside a high proportion of non cash earnings and recent share price volatility could limit how much credit investors are willing to give the stock, even though the same dataset shows the share price at €804.40 sitting far below the cited DCF fair value of €2,466.70.
  • The bearish narrative that margins could ease from 31.4% to 27.3% over the next few years leans on the current 32.3% trailing margin and rising R&D and SG&A expenses as evidence that higher spending might cap profitability.
  • However, the combination of forecast revenue growth of roughly 17% per year and earnings growth of about 22.1% per year is what clashes with bearish concerns, since those forecasts imply that even at a lower future margin, absolute earnings could still be well above today’s US$1.7 billion level.

If that mix of a premium 33.4x P/E, margin pressure, and strong growth forecasts is what you are weighing, it is exactly the tension bears and bulls are debating in their valuation arguments. 🐻 argenx Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for argenx on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of bullish and bearish narratives around argenx, it makes sense to look through the data yourself and decide how convincing each side really is before the next round of results reframes the story. To help you weigh the upside potential against the concerns on profitability and valuation, start by reviewing the 3 key rewards and 2 important warning signs.

See What Else Is Out There

For all the growth in argenx, the combination of a rich 33.4x P/E, moderating margins and heavy R&D and SG&A spending keeps valuation risk front and center.

If you feel that paying up for argenx's current earnings and margin profile asks a lot, it is worth comparing against companies highlighted in the 236 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com